Antiepilepsy Drugs Market - Forecast to 2027

Antiepilepsy Drugs market Information, Types of seizures (Generalized seizures and Partial-onset seizures), By Generation (First, second and third) - Forecast to 2027

ID: MRFR/Pharma/1729-HCR | February 2021 | Region: Global | 85 pages

Market Synopsis of Antiepilepsy Drugs Market :


Market Scenario:


Epilepsy is a group of neurological disorders characterized by seizures manifesting as brief, involuntary episodes of vigorous shaking of a part or complete body. The patient may experience loss or disturbance of consciousness and movements along with sensory or psychiatric disturbances. About 24 million people around the globe suffer from epilepsy with the antiepilepsy drugs market reaching USD 3.7 billion in 2015. Antiepilepsy drugs market is estimated that this market has the potential to reach USD 4.8 billion in 2022 representing a CAGR of 3.79%.


 The major driving factor for the antiepilepsy drugs market growth are:



  • Development of better-tolerated third-generation drugs

  • Increasing screening of patients, penetration, and availability of drugs

  • Growth of geriatrics as they are affected more by epilepsy

  • Comparative lower competition in anti-epilepsy drugs as most drugs act by similar action. Thus, the advent of a novel drug will make it a blockbuster with easy uptake and less marketing cost

  • Support for drug research and awareness created by social and government bodies

  • The constraints of the market are:

  • Loss of patents for a number of anti-epilepsy drugs such as Neurontin (2003) and Lyrica (scheduled in 2018)

  • Unknown origins and mechanism of action of epilepsy and concurrent lack of new novel acting drugs

  • Historical dominance of Gamma Aminobutyric Acid modulators and ion channel blockers, even though a sizeable segment of patients respond very poorly or none at all to these drugs

  • Associated side-effects, such as depression and suicide behavior, dizziness, fatigue, weight gain etc. of major class of drugs

  • High cost of clinical trials and extensive post market surveillance as it is difficult to separate cause and effect of drugs in epilepsy

  • Social stigma associated with epilepsy especially in the developing world


Study Objectives antiepilepsy drugs market:



  • To provide detailed analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the global antiepilepsy drugs market

  • To provide insights about factors affecting the antiepilepsy drugs market growth

  • To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.

  • To provide historical and forecast revenue of the antiepilepsy drugs market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.

  • To provide country level analysis of the market with respect to the current antiepilepsy drugs market size and future prospective

  • To provide country level analysis of the antiepilepsy drugs market for segments by type of seizures (seizures (generalized seizures and partial-onset seizures) and by generation (first, second and third)

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the antiepilepsy drugs market

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments globally. 


Global antiepilepsy drugs market, by Region 2015 & 2022 (USD million) Global anti epilepsy drugs market


Key Players for antiepilepsy drugs market:


Some of the key players for antiepilepsy drugs market are Pfizer, Inc., Johnson & Johnson, UCB Pharma Ltd., Abbott Laboratories, GlaxoSmithKline plc, Novartis International AG, Sanofi S.A., Shire Pharmaceuticals Limited and Cephalon Inc.


Segments:


Antiepilepsy drugs market has been segmented on the basis of types of seizures, generation, and region.

Regional Analysis of antiepilepsy drugs market:


Globally, North America is the largest market for anti-epilepsy drugs. Europe is the second-largest market for anti-epilepsy drugs. The developing region especially Asia Pacific is accounting for major newer cases due to greater screening and better health care facilities distribution. However, the developing regions market particularly Asia Pacific will be the fastest growing and is likely to be the key to the future.


The report for Antiepilepsy Drugs Market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions. 

Intended Audience:



  • Global anti-epilepsy drugs manufacturers

  • Global anti-epilepsy drugs suppliers

  • Research and development Laboratories

  • Market Research and Consulting Service Providers



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2022: USD 4.8 Billion
  • 2027: Significant Value
  •   CAGR   3.79% (2013-2022)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Billion)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Types of seizures, Generation
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Pfizer, Inc., Johnson & Johnson, UCB Pharma Ltd., Abbott Laboratories, GlaxoSmithKline plc, Novartis International AG, Sanofi S.A., Shire Pharmaceuticals Limited and Cephalon Inc.
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers

  • Development of better tolerated third generation drugs
  • Increasing screening of patients, penetration and availability of drugs
  • Growth of geriatrics as they are affected more by epilepsy


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    The antiepilepsy drugs market is projected grow at approximately 3.79% CAGR during the assessment period (2016-2022).

    The valuation of the Antiepilepsy drugs market is estimated to increase to USD 4.8 BN by the end of 2022.

    Rising per capita healthcare expenditure and increasing R&D for the therapeutic procedures of the condition are major drivers of the antiepilepsy drugs market.

    North America holds the largest share in the antiepilepsy drugs market, followed by Europe and the Asia Pacific, respectively.

    Johnson & Johnson, Pfizer, Inc., UCB Pharma Ltd., GlaxoSmithKline plc, Abbott, Novartis AG, Shire Pharmaceuticals Limited, Sanofi, and Cephalon Inc., are some of the major players operating in the antiepilepsy drugs market.

    Table of Contents

    1 Introduction

    1.1 Definition

    1.2 Scope of Study

    1.3 Research Objective

    1.4 Assumptions & Limitations

    1.5 Market Structure

    2 Research Methodology

    2.1 Research Process

    2.2 Primary Research

    2.3 Secondary Research

    3 Market Dynamics

    3.1 Drivers

    3.2 Restraints

    3.3 Opportunities

    3.4 Challenges

    3.5 Macroeconomic Indicators

    4 Market Factor Analysis

    4.1 Porter’s five forces model

    4.1.1 Bargaining Power of suppliers

    4.1.2 Bargaining Power of Customer

    4.1.3 Intensity of Competitor’s

    4.1.4 Threat of New Entrants

    5 Global anti-epilepsy drugs market, by Types Of Seizures

    5.1 Introduction

    5.1.1 Generalized seizures

    5.1.2 Partial-onset seizures

    5.1.3 Others

    6 Global anti-epilepsy drugs market, by Generation

    6.1 Introduction

    6.1.1 First generation

    6.1.2 Second generation

    6.1.3 Third generation

    7 Global anti-epilepsy drugs market, by Regions

    7.1 Introduction

    7.1.1 Americas

    7.1.1.1 North America

    7.1.1.2 South America

    7.1.2 Europe

    7.1.2.1 Germany

    7.1.2.2 France

    7.1.2.3 UK

    7.1.2.4 Italy

    7.1.2.5 Spain

    7.1.2.6 Rest of Europe

    7.1.3 Asia Pacific

    7.1.3.1 Japan

    7.1.3.2 China

    7.1.3.3 India

    7.1.3.4 Republic of Korea

    7.1.3.5 Rest of Asia Pacific

    7.1.4 Middle East & Africa

    8 Company Landscape

    8.1 Introduction

    8.1.1 Mergers Acquisitions

    8.1.2 Collaborations

    8.1.3 Release/New Product Launches

    8.1.4 Other (Expansion, Updates, Partnership)

    9 Company Profile

    9.1 Pfizer, Inc.

    9.1.1 Company Overview

    9.1.2 Product/Business Segment Overview

    9.1.3 Financials

    9.1.4 Key Developments

    9.1.5 SWOT Analysis

    9.2 Johnson & Johnson

    9.2.1 Overview

    9.2.2 Product/Business Segment Overview

    9.2.3 Financials

    9.2.4 Key Developments

    9.2.5 SWOT Analysis

    9.3 UCB Pharma Ltd.

    9.3.1 Overview

    9.3.2 Product/Business Segment Overview

    9.3.3 Financials

    9.3.4 Key Developments

    9.3.5 SWOT Analysis

    9.4 Abbott Laboratories

    9.4.1 Overview

    9.4.2 Product/Business Segment Overview

    9.4.3 Financials

    9.4.4 Key Developments

    9.4.5 SWOT Analysis

    9.5 GlaxoSmithKline plc

    9.5.1 Overview

    9.5.2 Product/Business Segment Overview

    9.5.3 Financials

    9.5.4 Key Developments

    9.5.5 SWOT Analysis

    9.6 Novartis International AG

    9.6.1 Overview

    9.6.2 Product/Business Segment Overview

    9.6.3 Financials

    9.6.4 Key Developments

    9.6.5 SWOT Analysis

    9.7 Sanofi S.A.

    9.7.1 Overview

    9.7.2 Product/Business Segment Overview

    9.7.3 Financials

    9.7.4 Key Developments

    9.7.5 SWOT Analysis

    9.8 Shire Pharmaceuticals Limited

    9.8.1 Overview

    9.8.2 Product/Business Segment Overview

    9.8.3 Financials

    9.8.4 Key Developments

    9.8.5 SWOT Analysis

    9.9 Cephalon Inc

    9.9.1 Overview

    9.9.2 Product/Business Segment Overview

    9.9.3 Financials

    9.9.4 Key Developments

    9.9.5 SWOT Analysis

    10 Others

    11 Appendix

    List of Tables

    TABLE 1 GLOBAL ANTI-EPILEPSY DRUGS MARKET, 2020-2027 (USD MILLION)

    TABLE 2 GLOBAL ANTI-EPILEPSY DRUGS MARKET, BY TYPES OF SEIZURES, 2020-2027 (USD MILLION)

    TABLE 3 GLOBAL ANTI-EPILEPSY DRUGS MARKET, BY GENERATION, 2020-2027 (USD MILLION)

    TABLE 4 GLOBAL ANTI-EPILEPSY DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION)

    List of Figures

    FIGURE 1 RESEARCH PROCESS

    FIGURE 2 PORTERS FIVE FORCES MODEL

    FIGURE 3 GLOBAL ANTI-EPILEPSY DRUGS MARKET, BY TYPES OF SEIZURES

    FIGURE 4 GLOBAL ANTI-EPILEPSY DRUGS MARKET, BY GENERATION

    FIGURE 5 GLOBAL ANTI-EPILEPSY DRUGS MARKET, BY REGION

    FIGURE 6 GLOBAL ANTI-EPILEPSY DRUGS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)